Uso de anfepramona, femproporex, mazindol e sibutramina no Tratamento de pacientes com sobrepeso ou obesidade: análise Farmacológica e clínica
2020; Volume: 6; Issue: 2 Linguagem: Inglês
ISSN
2526-1606
AutoresAna Paula Neves Bittencourt Duarte, Tânia Carmen Peñaranda Govato, Rafael Guzella de Carvalho, Luis Carlos Barbosa Pontes-Junior, Cíntia Leci Rodrigues, Gustavo Miranda Pires Santos, Lucas Antônio Duarte Nicolau, Renato Ribeiro Nogueira Ferraz, Francisco Sandro Menezes Rodrigues,
Tópico(s)Pharmacology and Obesity Treatment
ResumoObesity is a disorder of energy metabolism in which there is excessive triglyceride accumulation in adipose tissue. Today, there is increasing media appeal towards an ever-growing search for thinness. Thus, there is an increase in the use of anorexigens, also known as appetite suppressants, in an abusive and irrational manner, leading to the development of chronic diseases, such as type 2 diabetes mellitus, hypertension and cardiovascular diseases, besides causing severe adverse reactions, such as increased blood pressure, dry mouth, increased heart rate, insomnia, constipation, nervousness, among others. The main appetite suppressant drugs are: amfepramone, fenproporex, mazindol and sibutramine. The main objective of this article is to identify the main impacts on the cardiovascular system of the use of appetite suppressants. The present work is a theoretical research though bibliographic survey and search for on-topic articles. Searches will also be carried out in electronic databases. Conclusion: These drugs should be used with caution, as they present contraindications and serious side effects, and may even cause dependence.
Referência(s)